The estimated Net Worth of Inc Xencor is at least $11.7 Milión dollars as of 3 September 2021. Inc Xencor owns over 108,000 units of INmune Bio stock worth over $11,746,871 and over the last 3 years Inc sold INMB stock worth over $0.
Sign up
Inc Xencor INMB stock SEC Form 4 insiders trading
Inc has made over 1 trades of the INmune Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently Inc exercised 108,000 units of INMB stock worth $842,400 on 3 September 2021.
The largest trade Inc's ever made was exercising 108,000 units of INmune Bio stock on 3 September 2021 worth over $842,400. On average, Inc trades about 54,000 units every 0 days since 2021. As of 3 September 2021 Inc still owns at least 1,885,533 units of INmune Bio stock.
You can see the complete history of Inc Xencor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Inc Xencor's mailing address?
Inc's mailing address filed with the SEC is 111, West Lemon Avenue, Monrovia, El Monte, California, 91016, United States.
Insiders trading at INmune Bio
Over the last 5 years, insiders at INmune Bio have traded over $5,236,202 worth of INmune Bio stock and bought 82,618 units worth $534,813 . The most active insiders traders include Linda F Powers, Edgardo Jr Baracchini a Inc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of $117,087. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth $36,350.
What does INmune Bio do?
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
What does INmune Bio's logo look like?
Complete history of Inc Xencor stock trades at INmune Bio
INmune Bio executives and stock owners
INmune Bio executives and other stock owners filed with the SEC include:
-
Dr. Raymond Joseph Tesi M.D.,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
David J. Moss M.B.A.,
CFO, Treasurer & Sec. -
Dr. Raymond Joseph Tesi,
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman -
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR,
Chief Scientific Officer & Chief Manufacturing Officer -
Dr. Christopher J. Barnum,
Director of Neuroscience -
Joshua S. Schoonover Esq.,
Assoc. Gen. Counsel -
Scott Juda,
Director -
Inc Xencor,
-
Timothy J Schroeder,
Director -
Edgardo Jr Baracchini,
Director -
James Kelly Ganjei,
Director -
Linda F Powers,
-
Marcia Allen,
Director -
Raymond Joseph Tesi,
President and CEO -
Mark William Lowdell,
Chief Scientific Officer -
David J Moss,
Chief Financial Officer